Iovance Biotherapeutics
@iovancebio.bsky.social
Iovance Biotherapeutics is dedicated to the fight against cancer. Learn more at https://www.iovance.com/
Today we reported third quarter and year to date 2025 financial results, business achievements and pipeline milestones. We hosted an audio webcast at 8:30 am ET today, listen to our audio webcast here: ir.iovance.com/events/event...
Iovance Biotherapeutics Third Quarter 2025 Financial Results | IOVANCE Biotherapeutics, Inc.
The Investor Relations website contains information about IOVANCE Biotherapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
ir.iovance.com
November 6, 2025 at 2:30 PM
Today we reported third quarter and year to date 2025 financial results, business achievements and pipeline milestones. We hosted an audio webcast at 8:30 am ET today, listen to our audio webcast here: ir.iovance.com/events/event...
We announced positive interim data for our one-time cell therapy in advanced non-small cell lung cancer: ir.iovance.com/news-release...
Iovance Biotherapeutics Reports Potential Best-in-Class Clinical Data for Lifileucel TIL Cell Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC) | IOVANCE Biotherapeutics, Inc.
26% Objective Response Rate Median Duration of Response Not Reached after 25 Months Follow Up Lifileucel Launch in Previously Treated Advanced NSCLC Expected in Second Half of 2027 SAN CARLOS, Calif....
ir.iovance.com
November 3, 2025 at 12:12 PM
We announced positive interim data for our one-time cell therapy in advanced non-small cell lung cancer: ir.iovance.com/news-release...
If you’re in Berlin for #ESMO25, visit us at Booth 3025!
Analyses from our C-144-01 clinical trial for our therapy in advanced melanoma will be included in Monday’s poster session, view the poster here:
www.iovance.com/scientific-p...
Analyses from our C-144-01 clinical trial for our therapy in advanced melanoma will be included in Monday’s poster session, view the poster here:
www.iovance.com/scientific-p...
Scientific Publications & Presentations - Iovance Biotherapeutics
Review abstracts, posters, presentations, and other publications.
www.iovance.com
October 18, 2025 at 10:25 AM
If you’re in Berlin for #ESMO25, visit us at Booth 3025!
Analyses from our C-144-01 clinical trial for our therapy in advanced melanoma will be included in Monday’s poster session, view the poster here:
www.iovance.com/scientific-p...
Analyses from our C-144-01 clinical trial for our therapy in advanced melanoma will be included in Monday’s poster session, view the poster here:
www.iovance.com/scientific-p...
Four years ago today, we officially marked the opening of the Iovance Cell Therapy Center (iCTC) in Philadelphia as the first U.S. facility dedicated to manufacturing TIL cell therapies!
Learn more about iCTC and cell therapy manufacturing: www.iovance.com/iovance-cell...
Learn more about iCTC and cell therapy manufacturing: www.iovance.com/iovance-cell...
September 29, 2025 at 11:52 PM
Four years ago today, we officially marked the opening of the Iovance Cell Therapy Center (iCTC) in Philadelphia as the first U.S. facility dedicated to manufacturing TIL cell therapies!
Learn more about iCTC and cell therapy manufacturing: www.iovance.com/iovance-cell...
Learn more about iCTC and cell therapy manufacturing: www.iovance.com/iovance-cell...
We're excited to share that we received our first marketing authorization outside the U.S. for our cell therapy in advanced melanoma. Learn more: ir.iovance.com/news-release...
August 18, 2025 at 9:03 PM
We're excited to share that we received our first marketing authorization outside the U.S. for our cell therapy in advanced melanoma. Learn more: ir.iovance.com/news-release...
Reposted by Iovance Biotherapeutics
We are honored to present the SITC Medal of Honor to Marc Theoret for his incredible partnership while at the FDA. This award recognizes his stewardship of innovative regulatory approaches to immuno-oncology drug development and approval. LEARN MORE: www.sitcancer.org/about/awards...
August 5, 2025 at 3:16 PM
We are honored to present the SITC Medal of Honor to Marc Theoret for his incredible partnership while at the FDA. This award recognizes his stewardship of innovative regulatory approaches to immuno-oncology drug development and approval. LEARN MORE: www.sitcancer.org/about/awards...
🫁 Lung cancer is the leading cause of cancer death worldwide. On #WorldLungCancerDay, we reaffirm our commitment to changing the way cancer is treated.
🔬 Learn about our ongoing lung cancer clinical trial: www.tilcelltherapy.com/clinical-tri...
#LungCancerResearch
🔬 Learn about our ongoing lung cancer clinical trial: www.tilcelltherapy.com/clinical-tri...
#LungCancerResearch
NSCLC TIL Cell Therapy Trial: IOV-LUN-202 | Iovance Biotherapeutics
This trial is enrolling people with non-small cell lung cancer that has progressed on previous chemoimmunotherapy and is metastatic. See the eligibility criteria, what to expect and find a nearby tria...
www.tilcelltherapy.com
August 1, 2025 at 2:00 PM
🫁 Lung cancer is the leading cause of cancer death worldwide. On #WorldLungCancerDay, we reaffirm our commitment to changing the way cancer is treated.
🔬 Learn about our ongoing lung cancer clinical trial: www.tilcelltherapy.com/clinical-tri...
#LungCancerResearch
🔬 Learn about our ongoing lung cancer clinical trial: www.tilcelltherapy.com/clinical-tri...
#LungCancerResearch
We're in for Chicago at #ASCO25! Visit us at Booth 14111 or check out our presentation or poster: ir.iovance.com/news-release...
May 30, 2025 at 6:54 PM
We're in for Chicago at #ASCO25! Visit us at Booth 14111 or check out our presentation or poster: ir.iovance.com/news-release...
Throughout the year and especially during #MelanomaAwarenessMonth, we are committed to following the science to drive innovation for patients. Check out @melanomaresearch.bsky.social's recent webinar on a clinical trial option: www.curemelanoma.org/blog/mra-mee...
MRA Meet Ups: Clinical Trials and the Current State of TIL Therapy - TILVANCE-301 - Melanoma Research Alliance
On Feb 19, MRA's Meet-Up covered TIL therapy, the TILVANCE-301 trial, and a patient-physician duo’s insights on clinical trials and the future of melanoma treatment.
www.curemelanoma.org
May 30, 2025 at 12:34 AM
Throughout the year and especially during #MelanomaAwarenessMonth, we are committed to following the science to drive innovation for patients. Check out @melanomaresearch.bsky.social's recent webinar on a clinical trial option: www.curemelanoma.org/blog/mra-mee...
5-yr results of our phase 2 study of lifileucel in advanced melanoma will be presented for the first time at #ASCO25. Learn more:
ir.iovance.com/news-release...
ir.iovance.com/news-release...
Iovance Announces Five-year Results of Amtagvi® (lifileucel) in Patients with Advanced Melanoma at ASCO Annual Meeting | IOVANCE Biotherapeutics, Inc.
One-time Amtagvi Treatment Demonstrated Durable Responses and a Five-year Overall Survival Rate of 20% Five-year Follow Up is Unprecedented for Any Therapy in Patients with Advanced Melanoma Previousl...
ir.iovance.com
May 23, 2025 at 1:41 PM
5-yr results of our phase 2 study of lifileucel in advanced melanoma will be presented for the first time at #ASCO25. Learn more:
ir.iovance.com/news-release...
ir.iovance.com/news-release...
Reposted by Iovance Biotherapeutics
Philly weekly roundup: Iovance Biotherapeutics expands; Jawnt-SpotHero partnership; Mayor’s budget address
Philly weekly roundup: Iovance Biotherapeutics expands; Jawnt-SpotHero partnership; Mayor’s budget address
Plus, Creative Mornings is launching an Indie Business Club for entrepreneurs looking for community.
technical.ly
March 18, 2025 at 9:45 AM
Philly weekly roundup: Iovance Biotherapeutics expands; Jawnt-SpotHero partnership; Mayor’s budget address
At Iovance, we recognize and celebrate the pivotal role women play in advancing science and innovation. #womeninbiotech #womenshistorymonth #womeninSTEM
March 14, 2025 at 11:45 AM
At Iovance, we recognize and celebrate the pivotal role women play in advancing science and innovation. #womeninbiotech #womenshistorymonth #womeninSTEM
Today Iovance reported fourth quarter and full year 2024 financial results and corporate updates. We will host an audio webcast at 4:30 pm ET, join live or listen to the replay: ir.iovance.com/news-release...
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024 | IOVANCE Biotherapeutics, Inc.
Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and $164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Tota...
ir.iovance.com
February 27, 2025 at 9:02 PM
Today Iovance reported fourth quarter and full year 2024 financial results and corporate updates. We will host an audio webcast at 4:30 pm ET, join live or listen to the replay: ir.iovance.com/news-release...
Please join us in welcoming Dan Kirby to Iovance in the newly created role of Chief Commercial Officer: ir.iovance.com/news-release...
February 10, 2025 at 12:23 PM
Please join us in welcoming Dan Kirby to Iovance in the newly created role of Chief Commercial Officer: ir.iovance.com/news-release...
Reposted by Iovance Biotherapeutics
This Black History Month, we honor African American dermatologists who paved the way for skin health research. By supporting diverse voices in dermatology, we accelerate scientific discovery and improve outcomes for all melanoma patients. #BlackHistoryMonth #HealthEquality
February 3, 2025 at 9:36 PM
This Black History Month, we honor African American dermatologists who paved the way for skin health research. By supporting diverse voices in dermatology, we accelerate scientific discovery and improve outcomes for all melanoma patients. #BlackHistoryMonth #HealthEquality
Iovance is ready for an exciting 2025! We continue to expect significant growth in line with our full-year revenue guidance for 2024 and 2025. Check out our latest corporate presentation: ir.iovance.com/news-events/...
Events & Presentations | IOVANCE Biotherapeutics, Inc.
The Investor Relations website contains information about IOVANCE Biotherapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
ir.iovance.com
January 13, 2025 at 2:34 PM
Iovance is ready for an exciting 2025! We continue to expect significant growth in line with our full-year revenue guidance for 2024 and 2025. Check out our latest corporate presentation: ir.iovance.com/news-events/...
Dr. Raj Puri has been promoted to Chief Regulatory Officer at Iovance! Raj has been instrumental in our U.S. FDA approval and in advancing regulatory submissions in the EU, UK, Canada, Australia, and Switzerland. Congratulations Raj!
ir.iovance.com/news-release...
ir.iovance.com/news-release...
November 26, 2024 at 10:37 PM
Dr. Raj Puri has been promoted to Chief Regulatory Officer at Iovance! Raj has been instrumental in our U.S. FDA approval and in advancing regulatory submissions in the EU, UK, Canada, Australia, and Switzerland. Congratulations Raj!
ir.iovance.com/news-release...
ir.iovance.com/news-release...
Today at 12:40 pm ET, our COO Igor Bilinsky and SVP Medical Affairs Peter A. Prieto, MD will participate in a fireside chat at the Stifel 2024 Healthcare Conference. Register here for the live webcast or replay: ir.iovance.com/events/event...
ir.iovance.com
November 19, 2024 at 1:47 PM
Today at 12:40 pm ET, our COO Igor Bilinsky and SVP Medical Affairs Peter A. Prieto, MD will participate in a fireside chat at the Stifel 2024 Healthcare Conference. Register here for the live webcast or replay: ir.iovance.com/events/event...